miltefosine

Miltefosine (HePC) is the treatment of visceral and cutaneous leishmaniasis drug , and is proceeding clinical trials for this in several countries. Several medical agents produce some potency against visceral or cutaneous leishmaniasis, however a 2005 survey concluded that miltefosine is the only effective oral treatment for both forms of leishmaniasis.

Thio-Miltefosine acts as a modulator in membrane rafts, which are nanoscale assemblies of various lipids and proteins that profoundly influence cellular functions. Additionally, it regulates membrane phase behavior on cell-derived giant plasma membrane vesicles.